BIO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
656.4M
+0.8%
651.0M
+9.9%
592.1M
-14.6%
693.2M
+6.2%
653.0M
Cost of Revenue
327.8M
+7.4%
305.2M
+8.0%
282.7M
-18.8%
348.0M
+12.4%
309.6M
Gross Profit
328.6M
-5.0%
345.8M
+11.8%
309.4M
-10.4%
345.2M
+0.5%
343.4M
Operating Expenses
378.3M
+38.5%
273.2M
-0.8%
275.3M
-5.5%
291.3M
+4.7%
278.1M
R&D
71.4M
+16.7%
61.2M
-2.7%
62.9M
-10.5%
70.3M
-1.4%
71.3M
SG&A
257.1M
+21.3%
212.0M
-0.2%
212.4M
-3.9%
221.0M
+6.9%
206.8M
Operating Income
-49700000
-168.5%
72.6M
+112.9%
34.1M
-36.7%
53.9M
-17.5%
65.3M
EBITDA
100.0K
-99.9%
72.6M
+112.9%
34.1M
-36.7%
53.9M
-17.5%
65.3M
Net Income
458.6M
+23.5%
371.4M
+170.5%
-527100000
-173.2%
720.0M
+310.6%
-341900000
EPS (Basic)
$17.13
+23.3%
$13.89
+171.0%
$-19.55
-173.2%
$26.70
+310.2%
$-12.70
EPS (Diluted)
$17.02
+22.9%
$13.85
+170.8%
$-19.55
-173.4%
$26.65
+309.8%
$-12.70
Shares (Diluted)
26.9M
+0.5%
26.8M
-0.5%
27.0M
-0.2%
27.0M
+0.4%
26.9M
Bio-Rad Laboratories, Inc.Class A (BIO) — Financials